• Cy5 NHS Ester(Et): Identity and Evidence Limits

  2026-10-12

  Supplier documentation identifies Cy5 NHS ester(Et) as an amine-reactive fluorescent labeling reagent, but no matched research paper was available to independently establish performance, comparative value, or application-specific outcomes.

• CAR-M Immunotherapy in HCC: Promise and Boundaries

  2026-10-12

  A preclinical study describes an in situ CAR-macrophage strategy for hepatocellular carcinoma that combines GPC3 recognition with inflammatory signaling and disruption of the CD47–SIRPα phagocytosis checkpoint. The findings are mechanistically informative but remain limited to murine models and human organoid systems; they do not establish clinical efficacy, safety, durability, or applicability beyond the tested settings.

• How vIRD Shapes Poxvirus Inflammation

  2026-10-11

  Liu et al. examined how orthopoxviruses regulate RIPK3-dependent necroptosis and reported that a viral RIPK3-degradation factor, vIRD, suppresses inflammatory cell death while promoting viral replication and disease severity in experimental models. The evidence supports a virus–host mechanism, but its applicability beyond the studied viruses and animal systems remains limited.

• CX-5461 in Cancer Research: Evidence and Limitations

  2026-10-10

  CX-5461 is an RNA polymerase I inhibitor used to study ribosome biogenesis, DNA damage, mitotic catastrophe, autophagy, and cellular senescence in cancer models. This overview compares supplier-reported activity with a 2026 cervical cancer study and explains the evidence gaps that limit clinical interpretation.

• Polyethylenimine Linear (PEI) MW 40,000

  2026-10-09

  Polyethylenimine Linear, PEI MW 40,000, is a cationic DNA transfection reagent for in vitro studies. The product dossier describes serum-compatible use, transient gene expression applications, and condition-dependent reported efficiencies of 60%–80%, while a 2026 breast-cancer study provides a relevant gene-perturbation context without establishing that PEI was used.

• Okadaic Acid A4540: Product Overview

  2026-10-09

  Okadaic acid (A4540) is a marine-derived serine/threonine phosphatase inhibitor described for conceptual studies of PP1, PP2A, phosphorylation-dependent signaling, and apoptosis. No matched paper evidence was provided, so performance and applicability remain unconfirmed.

• GLT-1, CB1–CREB Signaling, and TBI Cognition

  2026-10-08

  A 2025 Biomolecules study links traumatic brain injury to transient GLT-1 loss, CB1–CREB disruption, neuronal apoptosis, and cognitive dysfunction in mice. Its findings position astrocytic glutamate regulation as a mechanistic connection between endocannabinoid signaling and post-traumatic neurological outcomes, while remaining limited to a preclinical model.

• Schwartz 2022: Better Cancer Drug Response Metrics

  2026-10-08

  Hannah R. Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent outcomes. This framework encourages cancer biology researchers to interpret response magnitude, composition, and timing together rather than treating a single viability endpoint as a complete measure of drug activity.

• Dasatinib Monohydrate and NET Biology in CML

  2026-10-07

  Dasatinib Monohydrate, also known as BMS-354825, is examined here through a distinct immunobiology lens: how kinase inhibition intersects with neutrophil extracellular traps in chronic myeloid leukemia. The analysis separates established target activity from emerging evidence on NET-associated vascular biology and defines appropriate translational limits.

• Ibuprofen: A Mechanism-to-Evidence Research Framework

  2026-10-07

  Ibuprofen is examined here as a mechanistic research tool rather than a generic anticancer agent. The article connects COX biology, colon cancer evidence, assay interpretation, and the distinct protein-binding insights from a mubritinib–albumin study.

• Pifithrin-α: Interpreting p53–Ferroptosis Evidence

  2026-10-06

  Pifithrin-α is a p53 inhibitor that helps researchers test whether p53 contributes causally to ferroptosis and neurotoxicity. This evidence-focused analysis explains what the 2025 deltamethrin study shows, where interpretation remains limited, and how PFTα fits broader apoptosis and radiation-response research.

• Kaempferol, NRF2, and Inflammatory Osteolysis

  2026-10-06

  A 2026 study identifies NRF2 as a direct molecular target of kaempferol and connects NRF2/HO-1 activation with reduced osteoclast activity, oxidative stress, and inflammatory bone loss. Its combination of binding, pathway, cellular, and animal evidence supports a mechanistic model, while the single disease model and pharmacological validation leave important questions about clinical transferability.

• Ran Lactylation, SIRT1, and Astrocyte Polarization

  2026-10-05

  A 2026 International Immunopharmacology study identifies Ran lactylation at lysine 123 as a non-histone mechanism linking lactate accumulation to STAT3 nuclear transport and astrocyte polarization after oxygen-glucose deprivation/reoxygenation. The findings extend lactylation research beyond histones while indicating that SIRT1 is an important regulator of this metabolic-epigenetic pathway in spinal cord injury models.

• CGRP/SP–Piezo2 Signaling in Trigeminal Neuralgia

  2026-10-05

  Liao et al. identify a Ca2+-dependent CGRP/SP–Piezo2 feedback loop that connects trigeminal root compression, neuroinflammation, and mechanical allodynia in a rat model of trigeminal neuralgia. The study provides a mechanistic framework for peripheral sensitization while also highlighting the limits of translating findings from rat trigeminal tissues to human disease.

• Microspheres Reshape the TME to Boost TIL Therapy

  2026-10-04

  Li et al. report alginate-based microspheres that combine hyaluronidase and CXCL9 to remodel the tumor microenvironment before tumor collection. In mouse models, this pretreatment increased TIL recovery and supported faster expansion, stronger cytotoxic activity, and improved antitumor effects after reinfusion.

8695 records 3/580 page Previous Next 12345 下5页 Last page